Andrew Fromkin
Board Member
Immunovant, Inc. (IMVT)Equibles does not estimate personal net worth.
Get an email with a short summary when Immunovant, Inc. publishes a filing, an earnings call transcript or a press release.
Get IMVT alertsAbout Andrew Fromkin
Andrew Fromkin is recorded as Board Member at Immunovant, Inc. (IMVT) since September 9, 2021. Immunovant, Inc. reported in an 8-K filed September 15, 2021 that Andrew Fromkin was appointed Series A preferred stock directors, effective September 9, 2021. Immunovant, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Immunovant, Inc. includes Eric Venker (CEO), Eric Venker, M.D. (CEO and Board Member), Eric Venker, M.D., Pharm.D. (CEO) and 7 others.
“Effective September 9, 2021, each of Frank M. Torti, M.D., Andrew Fromkin, Atul Pande, M.D. and Eric Venker, M.D. were elected as Series A preferred stock directors of Immunovant, each to serve until his successor is duly elected and qualified or until his earlier death, resignation or removal.”
Affiliation history
-
Current
2021-09-09–present
Company network
Leadership on record at Immunovant, Inc.
- Eric Venker CEO
- Eric Venker, M.D. CEO, Board Member
- Eric Venker, M.D., Pharm.D. CEO
- Dr. Frank M. Torti Chairman
- Renee Barnett CFO
- Tiago Girao CFO
- Melanie Gloria COO
- Jay S. Stout CTO
- W. Bradford Middlekauff General Counsel
- Atul Pande, M.D. Board Member